What We Already Know about This Topic
* Intraoperative management of pulmonary hypertension remains a tremendous clinical challenge
* This study evaluated and compared the hemodynamic repercussions of three frequently used volatile agents (isoflurane, desflurane, and sevoflurane) in the presence of pressure-overload right ventricular hypertrophy in a in situ rat heart model
What This Article Tells Us That Is New
* Desflurane produced minimal systemic and right ventricular effects most probably related to its ability to relatively preserve sympathetic tone, whereas sevoflurane—and to a lesser extent, isoflurane—caused large discrepancies in the left and right circulations, characterized by marked reduction in left ventricular afterload combined with reduced right ventricular inotropy raising the ratio of the pulmonary to systemic circulations to critical levels
UNDER the denomination of pulmonary hypertension (PH) are grouped five entities (pulmonary arterial hypertension; PH with left heart disease; PH associated with lung diseases and/or hypoxemia; PH due to chronic thrombotic and/or embolic disease; miscellaneous [revised World Health Organization classification])1
that all share in common hemodynamic modifications of the pulmonary vasculature leading to a chronically increased intravascular pressure, defined as a mean pulmonary arterial pressure above 25 mmHg at rest,2
and resulting in eventual right ventricular (RV) failure.
The prevalence of PH in the population is dependent on its etiology. In a French registry, the prevalence of pulmonary arterial hypertension was approximately 15 per million.3
Moreover, the number of patients with PH related to chronic left heart disease or chronic hypoxic states is far greater.4
An estimated prevalence of PH in patients with obstructive sleep apnea was approximately 15–20%.5
It is therefore not infrequent that anesthesiologists are confronted with such patients.
However, intraoperative management of PH is a tremendous challenge. Indeed, surgery is a period at significant risk for patients with PH. In a series of PH patients undergoing noncardiac surgery, the mortality rate was found to be 7%.6
The risk of developing a postoperative morbid event was up to 42%, with respiratory failure, cardiac dysrhythmia, and congestive heart failure being the leading causes. Another retrospective study reported that PH patients undergoing total hip or knee arthroplasty experienced an approximately 4- to 4.5-fold increased adjusted risk of mortality.7
It is therefore mandatory to take care of these patients with great concern during the perioperative period. The main goals are to maintain adequate preload, systemic vascular resistance (SVR), and ventricle contractility, as well as to prevent increases in pulmonary vascular resistance.8
In this view, the choice of the anesthetic agent should be highly regarded. Unfortunately, although it is known that nitrous oxide should be avoided because of concern of elevation in pulmonary vascular resistance with this gas, there are no clinical trials assessing the different volatile anesthetics. Furthermore, despite published animal studies on the effects of halogenated volatiles on the right ventricle and/or pulmonary circulation, the question of whether an anesthetic agent is more appropriately suited for PH patients is still unanswered.
We thus designed an experimental study to evaluate and compare the hemodynamic repercussions of three frequently used volatile agents (isoflurane, desflurane, and sevoflurane) in the presence of pressure-overload RV hypertrophy in a model of in situ
heart preparation in rats. We elected to use the well-described rodent model of chronic PH injecting a single subcutaneous dose of monocrotaline, a toxic pyrrolizidine alkaloid found in the plant Crotalaria spectabilis
, that causes acute and subacute damages of the peripheral vasculature of the lung through early adventitial inflammation followed by progressive smooth muscle hypertrophy in the media.9
Materials and Methods
Approval from the Ethics Committee for Animal Research of the University Medical Center and from the Cantonal Veterinary Office of Geneva, Switzerland, was achieved before the study was initiated. Handling of animals followed the guidelines laid out in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996).
Twenty-eight male adult Wistar rats (mean weight, 393 ± 57 g) were used for this study. Each rat was randomly assigned either to the control (n = 14) or to the monocrotaline group (n = 14). All rats were maintained in temperature- and humidity-controlled rooms with typical light-dark cycle and given standard chow and tap water ad libitum until the operating day. A single subcutaneous injection of monocrotaline (Crotaline C2401, Sigma–Aldrich, Buchs, Switzerland), 60 mg kg−1, was performed on day 1 in the monocrotaline group and the rats were observed and kept in the laboratory (including rats of the control group) during 28 days before instrumentation.
The rodents were anesthetized by halogenated volatile inhalation and intubated by direct laryngoscopy with a 14-gauge catheter (100% oxygen during induction until intubation). Spontaneous ventilation was maintained as long as the sternotomy was not performed to avoid acute positive pressure-induced circulatory decompensation, as was observed in a pilot study we conducted before these experiments. The halogenated volatile (isoflurane [Baxter, Volketswil, Switzerland], desflurane [Baxter, Volketswil, Switzerland] or sevoflurane [Abbott, Baar, Switzerland]) used for induction was randomly chosen and the anesthesia was maintained with the same volatile throughout the surgical preparation adjusted at a concentration allowing unreactive surgery (approximately 1.0–1.5 minimum alveolar concentration [MAC]). The left femoral artery and the left femoral vein were catheterized with 22-gauge catheters advanced into the inferior aorta and vena cava, respectively. Intravascular volume status was maintained by an infusion of sodium chloride 0.9% 0.4 ml · h−1. Before opening the chest, 10 mcg · kg−1 fentanyl (Sintetica, Mendrisio, Switzerland) were bolused before starting an infusion of 10 mcg · kg−1 · h−1 fentanyl. A bolus of 1 mg · kg−1 atracurium (GlaxoSmithKline, Münchenbuchsee, Switzerland) was also administered for muscular relaxation. Then, the sternotomy was performed to enter the chest and the rats were ventilated (40% O2 in air) with a constant volume-cycled rodent ventilator (tidal volume, 7 ml · kg−1; positive end-expiratory pressure, 2.5 cm H2O; respiratory rate, 70–80 min−1). A 3-0 polypropylene suture was placed around the inferior vena cava (IVC) for intermittent vascular occlusion analysis. Finally, an apical stab with a 30-gauge needle was made in the right ventricle before it was catheterized with a 1.9 F conductance pressure-volume (PV) catheter (Scisense Inc, London, Ontario, Canada). The catheter was advanced along the long axis of the ventricle. The correct position was determined by phase and magnitude signals, as well as by online visualization of the PV loops and ability to modify the PV loops when altering preload through IVC occlusion. After surgical preparation, an arterial blood sample was collected for hematocrit and blood gas analysis to check for gas exchange. The entire instrumentation process lasted approximately 60 min.
Airway pressure and respiratory gases (including precise expiratory concentration of halogenated volatiles) were continuously monitored (UltimaTM, Datex/Instrumentarium, Helsinki, Finland). Due to the small size of the rats compared with the relatively large gas sampling rate of the Datex monitor, expired gases were not directly sampled at the usual level of the intratracheal catheter but from a sidestream port connected to the expiratory tubing leading to the waste anesthetic gases scavenging system, 10 cm downstream the water-filled positive end-expiratory pressure device of the rodent ventilator. This allowed continuous and stable recording of expiratory gases concentration that are damped over the expiratory duration (i.e., not true end-expiration) resulting in measured carbon dioxide values of approximately 2.8–3.2% during normoventilation. The rats were placed on a homeothermic blanket system (Harvard Apparatus, Holliston, MA) to maintain body temperature at 37°C.
Assessment of Cardiovascular Function
The conductance catheter placed in the right ventricle was connected to the recently developed ADVantageTM
system (Scisense Inc). This system uses a continuous dynamic correction for parallel conductance and can be repeatedly calibrated in vivo
without the need for hypertonic saline.10
It was shown to accurately measure beat-by-beat pressure and volume in the mouse right ventricle.11
It allowed the continuous recording of ventricular pressure and volume, steady-state and dynamic PV loops during the temporarily occlusion of the vena cava, and the classic ventricular function parameters derived from these recordings. In addition, catheters introduced in the femoral artery and vein were connected to calibrated pressure transducers (Honeywell, Zürich, Switzerland), and allowed the recording of systemic arterial and venous pressures.
Each rat was exposed to stepwise increasing doses (MAC 0.5, 1.0, and 1.5) of isoflurane, desflurane, and sevoflurane. MAC 1.0 for isoflurane was 1.5%,12
MAC 1.0 for desflurane was 5.7%,13
and MAC 1.0 for sevoflurane was 2.7%.14
The sequence of anesthetics was determined by random chance.
Data Acquisition and Treatment
The various recorded variables were continuously recorded and stored at a sampling rate of 1,000 Hz via an analog/digital interface converter (Biopac System, Goleta, CA) on a personal computer. Data were then analyzed using waveform data acquisition/analysis software (AcqKnowledge, Biopac System) and further analyzed with Microsoft Excel.
Data were obtained first at MAC 0.5 and then under stepwise increase of gas concentrations. Hemodynamic measurements were collected at each anesthetic concentration of the same volatile after 5 min of equilibration. When the rats were exposed to another volatile, the measurements were collected after 20 min of equilibration. For each condition, analyzed data were obtained after a 5-s period of apnea at end-expiration (five stable cardiac cycles that were averaged), followed by gradual preload reduction through manual IVC occlusion, still during apnea. IVC occlusion generally yielded 10–20 cardiac cycles allowing off-line reconstruction of PV loops and their derived parameters.
The procedure for the PV loops analysis, adapted here for the right ventricle, was already described elsewhere.15
Briefly, PV loops were plotted during the IVC occlusion to define the end-systolic pressure-volume relationship (ESPVR), its linear slope measured in the operating range (Ees
, end-systolic elastance) and its volume-axis intercept (V0
) through logarithmic extrapolation of the ESPVR. Preload recruitable stroke work (PRSW), which is the slope of the stroke work–end-diastolic volume relationship, was also determined.16
From steady-state PV recordings, we derived the following parameters: heart rate, RV end-diastolic pressure (EDP), RV end-systolic pressure (ESP), RV end-diastolic volume (EDV), RV end-systolic volume, RV stroke volume (SV = EDV – end-systolic volume), RV cardiac output (CO = Heart Rate × SV), RV ejection fraction (EF = SV/EDV), the peak positive value of the time-derivative of RV pressure (dP/dtmax), the peak negative value of the time-derivative of RV pressure (dP/dtmin), RV preload-adjusted dP/dtmax (PAdP/dtmax = dP/dtmax/EDV), RV stroke work (SW = SV x [ESP-EDP]), the pulmonary arterial effective elastance (Ea = ESP/SV), the RV ventriculoarterial coupling efficiency (Ees/Ea), and the time relaxation constant τ, being defined as the time span between the time of dP/dtmin in the cycle to the point where the RV pressure signal drops below the EDP level.
From the arterial pulse pressure recordings, we derived: systolic and diastolic systemic arterial pressure, mean systemic arterial pressure (MAP), systemic pulse pressure and SVR (SVR = [MAP - inferior vena cava pressure]/CO), assuming that the left ventricular CO equals the RV CO. Finally, we computed the ratio of peak systolic RV pressure over peak systemic arterial pressure (right/left systolic vascular ratio, R/L) to characterize the beat to beat relationship between the right and left circulations.
Each of these steady-state parameters was averaged from five consecutive heart cycles during the stable apnea condition immediately preceding the IVC occlusion maneuver.
After sacrifice of the animals with potassium chloride under maximal volatile inhalation, the heart was dissected with the atria removed and frozen for morphometric analysis. The hearts were then cut to transverse slices of 2 mm and scanned. The midventricular slice was used to estimate the ratio of RV over left ventricular wall thickness ratio (using three lines with different directions passing through the center of the heart). The weight of the left ventricle (+ septum) and right ventricle were determined by reassembling the respective wall slices. A technical assistant, blinded to the rat’s group, handled the morphometric analysis.
Analyses were performed with GraphPad Prism®, version 5.04 (GraphPad Software, Inc., La Jolla, CA). Data are reported as means ± SD. Morphometric and blood gas analysis data between control and monocrotaline groups were compared using a Student unpaired t test. The effects of monocrotaline at the three drug concentrations were characterized by a two-way repeated measures ANOVA with drugs and treatments as factors, followed by Bonferroni posttests for multiple comparisons when P < 0.05. Furthermore, comparisons within the three volatiles in each treatment group were analyzed by a one-way repeated measures ANOVA, with Bonferroni correction. Relationships between selected variables were evaluated by linear correlation using Pearson correlation coefficient.
Twenty-eight rats were randomized. Of the 14 rats in the control group, we analyzed data from 12 rats; two rats were excluded because their baseline RV ESP was above 30 mmHg. In the monocrotaline group, one rat was found dead on the day of the experiment and two other rats died from acute hemodynamic decompensation during the surgical preparation. Therefore, we analyzed data from 11 rats.
Effects of Monocrotaline Injection
Morphometric data are reported in table 1
and macroscopic changes secondary to monocrotaline injection are shown in figure 1
. Mean heart weight and mean left ventricle weight were not different between the two groups, whereas mean right ventricle weight was statistically different between the control and the monocrotaline group (127 ± 31 mg vs.
163 ± 40 mg, respectively; P
= 0.025), as was the ratio of the right over left ventricle wall thickness (29.9 ± 7.0% vs.
41.8 ± 5.7%, respectively; P
shows blood gases at baseline and after the final recordings. Monocrotaline injection was associated with a relatively reduced PaO2
Hemodynamic values are presented in table 3
. At MAC 0.5 (baseline conditions), animals injected with monocrotaline presented an increased RV ESP (P
< 0.0001), R/L (P
< 0.0001), Ees
< 0.0001), Ea
< 0.0001), dP/dtmax
< 0.0001), PAdP/dtmax
< 0.0001), SW (P
< 0.0001) and PRSW (P
= 0.0007). The diastolic index, dP/dtmin
, was also significantly increased (P
< 0.0001). Figure 2
shows how RV PV loops were affected by monocrotaline in two representative rats during MAC 1.5 of the three different investigated inhalation agents, illustrating the change in the shape of the PV loops with monocrotaline, the increased ESP, the steepening of the ESPVR, and the increased Ea
Effects of Isoflurane
In the control group, increasing isoflurane concentration to MAC 1.5 produced its expected systemic vascular effects, i.e.
, a 40% decrease in SVR (P
< 0.0001) associated with profound hypotension (P
< 0.0001) and a moderately reduced heart rate (P
< 0.05; table 3
). At MAC 1.0, isoflurane had no significant effect on these systemic variables, except for an intermediately reduced MAP (P
< 0.001). Systemic vasodilation was accompanied by an increased venous return to the RV (15% rise in EDV at MAC 1.5, P
< 0.01) without changes in RV ESP and EDP nor SV or CO. However, because of the major effect on the systemic circulation, the R/L ratio was significantly increased at MAC 1.0 and MAC 1.5 (P
< 0.05 and P
< 0.0001, respectively). RV contractility, as measured by dP/dtmax
, was significantly decreased at MAC 1.5 (P
< 0.01 and P
< 0.001, respectively), whereas SW and PRSW remained unchanged. The slope of the RV ESPVR, Ees
, and its volume-axis intercept, V0
, were significantly affected by isoflurane at MAC 1.5, with a flattening and rightward shift of the ESPVR. Ea
did not change but the Ees
ratio was significantly decreased (P
< 0.05). Isoflurane also caused slight diastolic dysfunction, as demonstrated by an increased τ at MAC 1.5 (P
< 0.05), but no change in dP/dtmin
In the monocrotaline group, isoflurane produced similar dose-dependent effects as those seen in the control group (table 3
). Because of the monocrotaline-induced increased RV afterload and contractility during MAC 0.5 inhalation, increasing the concentration of isoflurane to MAC 1.5 induced in addition significant reduction in ESP, SW, PRSW, and dP/dtmin
that had not been observed in the control group. Despite these RV depressant effects secondary to isoflurane inhalation, values of ESP, Ees
, SW, PRSW, and dP/dtmin
as well as dP/dtmax
, and R/L remained significantly higher in the monocrotaline group compared with the control group during MAC 1.5 isoflurane inhalation.
Effects of Desflurane
In the control group, desflurane at MAC 1.5 reduced heart rate (P
< 0.01) and MAP (P
< 0.0001), but had no significant effect on systemic pulse pressure or SVR (table 3
). ESP (P
< 0.001), EDP (P
< 0.05), EDV (P
< 0.05), and the R/L ratio (P
< 0.0001) were all slightly though significantly increased. SV (P
< 0.05), CO (P
< 0.0001), and EF (P
< 0.001) decreased. Desflurane did not modify dP/dtmax
, SW, nor PRSW, but the PAdP/dtmax
was slightly diminished (P
< 0.05). Although Ees
were not altered, Ea
was increased (P
< 0.001) resulting in a reduced Ees
< 0.05). Diastolic function was slightly improved, as shown by a higher dP/dtmin
< 0.05) despite the unchanged dP/dtmax
; τ remained stable.
In the monocrotaline group, desflurane produced similar dose-dependent effects as those seen in the control group (table 3
). However, SV and EF were not reduced and CO decreased slightly secondary to the decreased heart rate. RV dP/dtmax
and SW were reduced, whereas the preload-adjusted indices PAdP/dtmax
and PRSW remained stable. As with isoflurane, monocrotaline-induced increased afterload and contractility indices remained significantly higher in the monocrotaline group compared with the control group during MAC 1.5 desflurane inhalation.
Effects of Sevoflurane
In the control group, sevoflurane produced major dose-dependent decreases of systemic hemodynamics, i.e., SVR, MAP, systemic pulse pressure, and heart rate (P < 0.0001 for all variables). RV ESP was also slightly though significantly reduced (P < 0.0001), and the R/L ratio increased more than twofold (P < 0.0001). Contractility indices dP/dtmax, PAdP/dtmax, SW, and PRSW were also intensely decreased (35–40% at MAC 1.5; P < 0.0001). The combined systemic vascular and cardiac effects resulted in a reduced ejection capacity with diminished SV, EF, and CO (P < 0.0001), associated with an increased EDV (P < 0.0001). Sevoflurane did not modify Ees, Ea, and Ees/Ea, but V0 increased (P < 0.0001). Finally, sevoflurane also reduced diastolic function, as shown by the decrease in dP/dtmin (P < 0.0001) and the increased τ (P < 0.0001).
In the monocrotaline group, sevoflurane produced similar dose-dependent effects as those seen in the control group (table 3
), except for PRSW, which was not statistically decreased because of a large individual variability with this index. As was observed with isoflurane and desflurane, afterload and contractility indices remained significantly higher in the monocrotaline group and ejection indices were maintained at similar values as those recorded in the control group.
Differences between the Halogenated Volatiles
In the control group, baseline hemodynamic values (i.e.
, MAC 0.5) were similar for the three volatiles (table 3
). However, the investigated volatile agents produced major and significantly different variations in systemic and RV hemodynamics following stepwise increases in MAC. On the systemic circulation, sevoflurane produced the most profound drop in MAP, systemic pulse pressure, and SVR, followed by isoflurane, then by desflurane. Sevoflurane was also associated with the most important alterations of RV systolic and diastolic functions, again followed by isoflurane, then by desflurane. On the other hand, desflurane was the only drug to increase ESP and EDP, associated with a significant increase in Ea
As was the case with the control group, systolic and diastolic functions in the monocrotaline group were more affected by sevoflurane. It should be noted that despite the fact that ESP and Ea
were higher with desflurane and that pulmonary vascular resistance seemed enhanced as suggested by the relatively steeper relationship between ESP and CO compared with isoflurane and sevoflurane in figure 3
, this was not associated with a reduced contractility, dP/dtmax
or SW and PRSW showing little or no variations of their values with increasing desflurane concentrations. RV contractility was even more preserved with desflurane compared with the two other volatiles. Finally, R/L was doubled under the high sevoflurane exposure to almost reach equality between the RV systolic pressure and the systemic systolic arterial pressure (0.82 ± 0.14). At MAC 1.5, R/L was statistically higher with sevoflurane than with the other two agents. On the other hand, desflurane remained statistically lower compared with isoflurane or sevoflurane (fig. 4
Model of Compensated, Pressure-overload RV Hypertrophy
After monocrotaline injection, right ventricle weight and wall thickness were increased (fig. 1
, table 1
) and PaO2
levels were lower (table 2
), the latter being most probably secondary to moderate ventilation/perfusion mismatches. ESP and Ea
were increased, demonstrating indirectly that pulmonary arterial pressure was genuinely increased. The right ventricle adapted through concentric hypertrophy, further evidenced by changes in diastolic function.
was steeper in the monocrotaline group, suggesting increased contractility, but as already reported both for the left ventricle,15
and the right ventricle,16
this could be only secondary to the increased afterload. V0
, on the other hand, was not significantly increased. PRSW was previously demonstrated to be the most reliable index of RV contractile performance.16
However, our results show that PRSW cannot be applied to pressure-overload RV hypertrophy. Whereas the correlation coefficient of the relationship between dP/dtmax
and PRSW was quite satisfactory in the control group (R2
= 0.646), it was very poor in the monocrotaline group (fig. 5
). This can partly be explained by a large individual variation for PRSW in the monocrotaline group, which was not the case with the simultaneously recorded dP/dtmax
values. Because of concerns about the validity of indices derived from PV loop analysis in hypertrophied RV, dP/dtmax
were considered throughout this study as reference contractile indices (note the high correlation coefficient between dP/dtmax
in both groups [fig. 5
]). One can argue that dP/dtmax
is afterload dependent and was then increased in the monocrotaline group only because of enhanced afterload. However, CO and EF were identical in both groups, despite higher SW in the monocrotaline group. This could not have been the case without an effective enhanced contractility.
We also measured the Ees
ratio, because this index has been shown to measure RV contractility and coupling efficiency during pulmonary hypertension and RV failure.17–20
Ventriculoarterial coupling was not statistically altered by monocrotaline injection, confirming the relatively compensated nature of our pathophysiologic animal model.
Finally, monocrotaline administration had minimal effects on the systemic circulation. It was manifested essentially by a slight reduction in MAP with no significant changes in SVR, probably secondary to systemic toxic effects.21
Effects of the Halogenated Volatiles
All three halogenated volatiles produced consistent systemic hemodynamic variations, but the magnitude of these variations were clearly dependent on the volatiles used. Although desflurane decreased MAP by approximately 20–25% at MAC 1.5, MAP was decreased by 60–65% with sevoflurane; isoflurane produced intermediate effects. Moreover, desflurane did not significantly affect SVR, whereas sevoflurane induced profound vasodilation. Surprisingly, these disparities of the three investigated agents on SVR have not previously been specifically reported.19
This discrepancy may be related to species differences, differing baseline systemic vascular tone, disparate applied drug concentrations, but most probably also to the experimental protocol used. For instance, in a rabbit study,23
the concentrations of the inhalation agents were adjusted to the individual animal’s response to deep paw pinch compared with the strictly imposed MAC of the current study, resulting in differing baseline and final MAC between studies. Rabbits were further hyperventilated to avoid spontaneous breathing during recordings while we supplemented general anesthesia with a continuous infusion of fentanyl and atracurium to prevent this occurrence. These differences may have influenced the underlying sympathetic tone between the studies, a consequence that is especially relevant for the cardiovascular effects of desflurane.24
On the right circulation, there was no major vasodilation of the pulmonary vasculature in the control group, even with the potent systemic vasodilating sevoflurane, as assessed by Ea
, or indirectly by ESP. This is in agreement with previous studies demonstrating that isoflurane, desflurane, and sevoflurane do not affect the pulmonary arterial pressure-flow relationship, i.e.
, vascular tone.25–27
During conditions of an increased RV afterload, ESP was reduced with isoflurane and sevoflurane, but this decrease was clearly flow-related (fig. 3
), indicating that these agents did not actively vasodilate the pulmonary vasculature during the relatively fixed monocrotaline-induced PH.
It should be observed that the common cardiac functional indices used in clinical practice, i.e.
, CO and EF, are not sensitive enough to distinguish between halogenated volatiles in the presence of pressure-overload RV hypertrophy. This is also true for the indices derived from the PV loops. Indeed, whereas the hemodynamics were profoundly disturbed by sevoflurane and isoflurane, neither Ees
nor the Ees
ratio showed consistent changes in myocardial contractility and coupling efficiency and therefore did not add substantial information in this respect. The large variability of the PRSW index also precluded its use in this situation. The aptitude to detect dysfunction of the right ventricle with PV loop-derived contractility indices was therefore limited; in any case, V0
seemed a more reliable index. In contrast, PAdP/dtmax
was much more consistent with observed and coherent contractility changes. This index has previously been shown to be preload and afterload independent, at least for the left ventricle.15
The current study shows that isoflurane, desflurane, and sevoflurane exhibit different effects on the RV systolic and diastolic function in the presence of pressure-overload RV hypertrophy. Of interest, we have shown that desflurane is the best choice, sevoflurane the worst. RV contractility was indeed better preserved with desflurane. However, a better RV contractility does not by itself explain why rats were more stable under desflurane exposure, because, at all times and under all volatiles, dP/dtmax and PAdP/dtmax remained higher in the monocrotaline versus control group. More importantly, systemic hemodynamics, especially LV afterload, were less altered by desflurane.
The right-to-left gradient of vascular pressures is conserved under desflurane and prevents the left ventricle from being crushed by the right ventricle through septal ballooning, leading to reduced LV compliance and filling. This point is best demonstrated by analysis of the R/L ratio, which was less increased with desflurane than with the two other volatiles (fig. 4
). It should be observed that with sevoflurane, R/L was close to 1, meaning that pressures in the pulmonary circulation almost equaled pressures in the systemic circulation. The relationship between PAdP/dtmax
and R/L shows that a reduction in RV contractility is directly associated with a concomitant increase in R/L (fig. 6
). After monocrotaline injection, the x-axis intercept of this relationship is displaced to the right while the slope remains identical. This means that for any given PAdP/dtmax
value, R/L will be closer to 1 in the presence of a pressure-overload RV hypertrophy. One can understand that the slightest decrease in left ventricle myocardial contractility becomes harmful. Moreover, if left ventricle afterload is suddenly decreased, acute heart failure can happen even at high levels of RV contractility. This implies that it is safer to keep systemic hemodynamics in physiologic ranges, rather than trying to decrease the pulmonary vascular pressures by choosing a specific halogenated volatile more prone to induce pulmonary vasodilation, at the cost of also altering systemic pressures. Indeed, if we had based our interpretation only on the right circulation regardless of the left, sevoflurane would have seemed the ideal drug because RV afterload was apparently reduced. However, based on R/L, it would be strongly recommended not to use sevoflurane in this setting, but rather to choose desflurane to avoid an acute left ventricle failure secondary to reduced filling of the rats’ left ventricle.
We studied an animal model of PH and pressure-overload RV hypertrophy secondary to monocrotaline injection, a condition known to be curable by many different pharmacologic agents.28
The pathophysiologic model is therefore not necessarily identical to what can be observed in established clinical PH. Nonetheless, monocrotaline’s repercussion on the right ventricle, i.e.
, pressure-overload hypertrophy, is not different from any chronic compensatory ventricle change associated with increased afterload observed in sustained PH.
Hemodynamic data related to the left ventricle are lacking. Clearly, left contractility indices would have been valuable to better understand how the hypertrophied right ventricle affects the left ventricle. It was yet technically difficult to introduce a second catheter in the left ventricle and harmful to already sick, potentially unstable rats. Artifacts caused by the presence of two catheters in the heart also prevented reproducible measures of good quality. We decided to record systemic variations through a femoral catheter advanced into the aorta and to assume that CO was identical in the left and in the right ventricles. It was also for technical reasons that we did not measure pressures or resistances in the pulmonary vasculature.
The current study was conducted in open-chest animals, abolishing chest wall-heart interaction. In a closed chest, the described effects on the R/L ratio would have been amplified and its potentially harmful consequences even more readily obtained. This last point is further supported by the observation that the two rats injected with monocrotaline that died during the surgical preparation were anesthetized with sevoflurane, the agent associated with the highest R/L ratio.
Finally, the statistical analysis used a two-way repeated measures ANOVA that was followed by Bonferroni posttests when P < 0.05. We understand that multiplicity is problematic as repeating the procedure for the three dosages is not adjusted. However, many comparisons were needed to illustrate the behavior of each drug. The interpretation of the individual main effects is also made easier (each effect has its own exact P value).
The current results demonstrate that in rats the cardiovascular properties of the halogenated volatiles commonly used in clinical practice are not equal and that their use may present substantial hemodynamic risks in the setting of pressure-overload RV hypertrophy. Desflurane produced minimal systemic and RV effects most probably related to its ability to relatively preserve sympathetic tone, whereas sevoflurane—and to a lesser extent isoflurane—cause large discrepancies on the left and right circulations, characterized by marked reduction in LV afterload combined with reduced RV inotropy, increasing the ratio of the pulmonary to systemic circulations to critical levels. The R/L ratio should be taken into account when evaluating inhalation anesthetics because the classic PV loop derived as well as clinical performance indices are not sufficiently sensitive to detect these critically risky conditions. Because of the probable underestimated prevalence of PH in the general populations undergoing general anesthesia, these findings may have a significant effect on the management of patients with acute or chronic PH. Validation of these experimental data in clinical practice should therefore be encouraged.
The authors thank Manuel Jorge-Costa (Technical Assistant, Faculty of Medicine, University of Geneva, Geneva, Switzerland), Michèle Brunet (Technical Assistant, Faculty of Medicine, University of Geneva), and Sylvie Roulet (Technical Assistant, Faculty of Medicine, University of Geneva) for excellent technical assistance.
1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–54
2. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55–66
3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30
4. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. American College of Cardiology Foundation Task Force on Expert Consensus Documents, American Heart Association, American College of Chest Physicians, American Thoracic Society, Inc, Pulmonary Hypertension Association: ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619
5. Kessler R, Chaouat A, Weitzenblum E, Oswald M, Ehrhart M, Apprill M, Krieger J. Pulmonary hypertension in the obstructive sleep apnoea syndrome: Prevalence, causes and therapeutic consequences European Respiratory Journal. 1996;9:787
6. Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: Predictors of perioperative morbidity and mortality. J Am Coll Cardiol. 2005;45:1691–9
7. Memtsoudis SG, Ma Y, Chiu YL, Walz JM, Voswinckel R, Mazumdar M. Perioperative mortality in patients with pulmonary hypertension undergoing major joint replacement. Anesth Analg. 2010;111:1110–6
8. Pritts CD, Pearl RG. Anesthesia for patients with pulmonary hypertension. Curr Opin Anaesthesiol. 2010;23:411–6
9. Wilson DW, Segall HJ, Pan LC, Dunston SK. Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats. Microvasc Res. 1989;38:57–80
10. Clark JE, Kottam A, Motterlini R, Marber MS. Measuring left ventricular function in the normal, infarcted and CORM-3-preconditioned mouse heart using complex admittance-derived pressure volume loops. J Pharmacol Toxicol Methods. 2009;59:94–9
11. Tabima DM, Hacker TA, Chesler NC. Measuring right ventricular function in the normal and hypertensive mouse hearts using admittance-derived pressure-volume loops. Am J Physiol Heart Circ Physiol. 2010;299:H2069–75
12. Mazze RI, Rice SA, Baden JM. Halothane, isoflurane, and enflurane MAC in pregnant and nonpregnant female and male mice and rats. Anesthesiology. 1985;62:339–41
13. Eger EI 2nd, Johnson BH. MAC of I-653 in rats, including a test of the effect of body temperature and anesthetic duration. Anesth Analg. 1987;66:974–6
14. Kashimoto S, Furuya A, Nonaka A, Oguchi T, Koshimizu M, Kumazawa T. The minimum alveolar concentration of sevoflurane in rats. Eur J Anaesthesiol. 1997;14:359–61
15. Blaudszun G, Morel DR. Relevance of the volume-axis intercept, V0, compared with the slope of end-systolic pressure-volume relationship in response to large variations in inotropy and afterload in rats. Exp Physiol. 2011;96:1179–95
16. Karunanithi MK, Michniewicz J, Copeland SE, Feneley MP. Right ventricular preload recruitable stroke work, end-systolic pressure-volume, and dP/dtmax-end-diastolic volume relations compared as indexes of right ventricular contractile performance in conscious dogs. Circ Res. 1992;70:1169–79
17. Wauthy P, Abdel Kafi S, Mooi WJ, Naeije R, Brimioulle S. Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension. J Thorac Cardiovasc Surg. 2003;126:1434–41
18. Wauthy P, Pagnamenta A, Vassalli F, Naeije R, Brimioulle S. Right ventricular adaptation to pulmonary hypertension: An interspecies comparison. Am J Physiol Heart Circ Physiol. 2004;286:H1441–7
19. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P, Naeije R, Brimioulle S. Isoflurane and desflurane impair right ventricular-pulmonary arterial coupling in dogs. Anesthesiology. 2004;101:1357–62
20. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P, Naeije R, Brimioulle S. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2004;32:1035–40
21. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 1993;73:887–97
22. Hettrick DA, Pagel PS, Warltier DC. Desflurane, sevoflurane, and isoflurane impair canine left ventricular-arterial coupling and mechanical efficiency. Anesthesiology. 1996;85:403–13
23. Royse CF, Liew DF, Wright CE, Royse AG, Angus JA. Persistent depression of contractility and vasodilation with propofol but not with sevoflurane or desflurane in rabbits. Anesthesiology. 2008;108:87–93
24. Ebert TJ, Muzi M. Sympathetic hyperactivity during desflurane anesthesia in healthy volunteers: A comparison with isoflurane. Anesthesiology. 1993;79:444–53
25. Priebe HJ. Differential effects of isoflurane on regional right and left ventricular performances, and on coronary, systemic, and pulmonary hemodynamics in the dog. Anesthesiology. 1987;66:262–72
26. Lennon PF, Murray PA. Isoflurane and the pulmonary vascular pressure-flow relation at baseline and during sympathetic alpha- and beta-adrenoreceptor activation in chronically instrumented dogs. Anesthesiology. 1995;82:723–33
27. Lesitsky MA, Davis S, Murray PA. Preservation of hypoxic pulmonary vasoconstriction during sevoflurane and desflurane anesthesia compared to the conscious state in chronically instrumented dogs. Anesthesiology. 1998;89:1501–8
28. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:1013–32
© 2012 American Society of Anesthesiologists, Inc.